Patients were randomly assigned to bevacizumab with paclitaxel @ mg/m ( @ ) ( arm A ) , nab-paclitaxel @ mg/m ( @ ) ( arm B ) , or ixabepilone @ mg/m ( @ ) ( arm C ) , once per week for @ of @ weeks .